 |
answer text |
<p>Following their review, the Adrenaline Auto-injector Expert Working Group (AAI
EWG) recommended in principle that adrenaline auto-injectors (AAIs) should be made
available in public locations, for use in treating anaphylaxis in unforeseen and critical
circumstances, provided suitable safeguards can be implemented to ensure their effective
and safe use. Challenges lie in ensuring correct and secure storage of AAIs, to ensure
that the adrenaline does not deteriorate, and the device remains functional. Cinemas
offering food for sale and other food outlets were identified as examples of locations
where emergency AAIs might have particular potential to save lives.</p><p>The legislative
change will therefore concern AAI supply, to specify or define individuals or organisations
with the necessary competence to obtain and store AAIs for use in the event of an
anaphylactic emergency. The AAI EWG advised the need for access to AAIs in a broad
range of settings such as restaurants, gyms, cinemas, childcare facilities, youth
groups, and music festivals. To support such wide-ranging access, the scope of legal
supply will need to be linked to a requirement for training, to support safe use.</p><p>An
Expert Advisory Group for Allergy was established in 2023, across the Government and
clinical organisations, and chaired by the National Allergy Strategy Group and the
Department, to recommend further action by the Medicines and Healthcare products Regulatory
Agency (MHRA), Department of Health and Social Care, Department for Education, and
the National Health Service. The Department of Health and Social Care and the MHRA
are currently considering updates to the 2017 guidance, to ensure that any updated
clarifications are supported by evidence, and that any open questions are answered.</p>
|
|
